The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}

Kurt Miller; Per Anders Abrahamsson; Koichiro Akakura; Frans M J Debruyne; Christopher P Evans; Laurence Klotz

doi:10.1016/j.eursup.2006.12.001

The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}

Kurt Miller, Per Anders Abrahamsson, Koichiro Akakura, Frans M J Debruyne, Christopher P Evans, Laurence Klotz

Urology

Research output: Contribution to journal › Article › peer-review

7 Scopus citations

Abstract

Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.

Original language	English (US)
Pages (from-to)	327-333
Number of pages	7
Journal	European Urology, Supplements
Volume	6
Issue number	3
DOIs	https://doi.org/10.1016/j.eursup.2006.12.001
State	Published - Mar 2007

Keywords

Prostate cancer
PSA
PSA doubling time
PSA velocity

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eursup.2006.12.001

Fingerprint Dive into the research topics of 'The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}'. Together they form a unique fingerprint.

Cite this

@article{cf3f603a4f8b43aaa4ebc52d152cf742,

title = "The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}",

abstract = "Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.",

keywords = "Prostate cancer, PSA, PSA doubling time, PSA velocity",

author = "Kurt Miller and Abrahamsson, {Per Anders} and Koichiro Akakura and Debruyne, {Frans M J} and Evans, {Christopher P} and Laurence Klotz",

year = "2007",

month = mar,

doi = "10.1016/j.eursup.2006.12.001",

language = "English (US)",

volume = "6",

pages = "327--333",

journal = "European Urology, Supplements",

issn = "1569-9056",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - The Continuing Role of PSA in the Detection and Management of Prostate Cancer{A figure is presented}

AU - Miller, Kurt

AU - Abrahamsson, Per Anders

AU - Akakura, Koichiro

AU - Debruyne, Frans M J

AU - Evans, Christopher P

AU - Klotz, Laurence

PY - 2007/3

Y1 - 2007/3

N2 - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.

AB - Despite being used extensively for the diagnosis and management of prostate cancer, prostate-specific antigen (PSA) testing remains controversial. Doubts have been raised over the continued use of PSA in the detection of clinically significant prostate cancer because many men now present with early-stage, small-volume tumours. This article examines the limitations of using a single PSA value in diagnosis and discusses alternative approaches to PSA testing, in particular PSA velocity and PSA doubling time, which are now emerging as valuable pretreatment disease predictors. A clinical scenario is also presented to illustrate the use of PSA kinetics in identifying candidates for biopsy.

KW - Prostate cancer

KW - PSA

KW - PSA doubling time

KW - PSA velocity

UR - http://www.scopus.com/inward/record.url?scp=33846408703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846408703&partnerID=8YFLogxK

U2 - 10.1016/j.eursup.2006.12.001

DO - 10.1016/j.eursup.2006.12.001

M3 - Article

AN - SCOPUS:33846408703

VL - 6

SP - 327

EP - 333

JO - European Urology, Supplements

JF - European Urology, Supplements

SN - 1569-9056

IS - 3

ER -